MwanzoALMKT • EPA
add
Mauna Kea Technologies SA
Bei iliyotangulia
€ 0.070
Bei za siku
€ 0.070 - € 0.075
Bei za mwaka
€ 0.061 - € 0.21
Thamani ya kampuni katika soko
12.79M EUR
Wastani wa hisa zilizouzwa
1.12M
Uwiano wa bei na mapato
-
Mgao wa faida
-
Ubadilishanaji wa msingi
EPA
Habari za soko
Fedha
Taarifa ya Mapato
Mapato
Mapato halisi
| (EUR) | Jun 2025info | Mabadiliko Tangu Mwaka Uliopita |
|---|---|---|
Mapato | 2.02M | -5.58% |
Matumizi ya uendeshaji wa biashara | 3.02M | -13.98% |
Mapato halisi | -2.33M | 0.36% |
Kiwango cha faida halisi | -115.83 | -5.52% |
Mapato kwa kila hisa | — | — |
EBITDA | -1.35M | 12.08% |
Asilimia ya kodi ya mapato | -1.21% | — |
Taarifa ya Hali ya Kifedha
Jumla ya mali
Jumla ya dhima
| (EUR) | Jun 2025info | Mabadiliko Tangu Mwaka Uliopita |
|---|---|---|
Uwekezaji wa pesa taslimu na vipindi vifupi | elfu 663.00 | -82.63% |
Jumla ya mali | 12.66M | -30.23% |
Jumla ya dhima | 42.08M | 9.33% |
Jumla ya hisa | -29.42M | — |
hisa zilizosalia | 79.74M | — |
Uwiano wa bei na thamani | -0.19 | — |
Faida inayotokana na mali | -27.57% | — |
Faida inayotokana mtaji | -101.28% | — |
Mtiririko wa pesa
Mabadiliko halisi ya pesa taslimu
| (EUR) | Jun 2025info | Mabadiliko Tangu Mwaka Uliopita |
|---|---|---|
Mapato halisi | -2.33M | 0.36% |
Pesa kutokana na shughuli | -1.10M | 41.90% |
Pesa kutokana na uwekezaji | elfu 116.00 | 217.81% |
Pesa kutokana na ufadhili | elfu 336.50 | 248.57% |
Mabadiliko halisi ya pesa taslimu | elfu -677.00 | 67.54% |
Mtiririko huru wa pesa | elfu -460.56 | 43.00% |
Kuhusu
Mauna Kea Technologies is a global medical device company focused on endomicroscopy, the field of microscopic imaging during endoscopy procedures. The company researches, develops and markets tools to visualize, detect, and rule out abnormalities including malignant and pre-malignant tumors or lesions in the gastrointestinal and pulmonary tracts.
The company makes Cellvizio, a probe-based Confocal Laser Endomicroscopy system, which provides physicians and researchers with real-time access to histological information during standard endoscopy procedures through high-resolution cellular imaging of internal tissues.
Cellvizio is used in medical applications such as gastrointestinal endoscopy, pulmonology and urology to help physicians diagnose lesions and make accurate treatment decisions in real-time.
Cellvizio went public in July 2011 and trades on the Euronext Paris exchange. Wikipedia
Afisa Mkuu Mtendaji (CEO)
Ilianzishwa
2000
Tovuti
Wafanyakazi
61
